TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06166160

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bulk fill flowable composite SDR Dentsply sirona
Description: caries removal in class II cavities of primary molars and application of experminted restorations

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bulk fill flowable composite SDR Dentsply sirona
Description: caries removal in class II cavities of primary molars and application of experminted restorations
Study: NCT06102759

Intervention type: DRUG
Intervention: Adebrelimab，Fruquintinib
Description: Adebrelimab，Fruquintinib combined with chemotherapy
Study: NCT04869137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib Oral Product
Description: 20mg of Lenvatinib will be taken orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200mg of Pembrolizumab will be administered through IV infusion every 3 weeks.
Study: NCT05021562

Intervention type: DRUG
Intervention: Niraparib
Description: Niraparib capsules
Study: NCT06411418

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pipeline™ Flex Embolization Device with Shield Technology™
Description: The Pipeline™ Flex Embolization Device with Shield Technology™ for the endovascular treatment of adults (22 years of age or older) with large or giant wide-necked intracranial aneurysms (IAs) in the internal carotid artery from the petrous to the superior hypophyseal segments. The Pipeline™ Flex Embolization Device with Shield Technology™ is also indicated for use in the internal carotid artery up to the terminus for the endovascular treatment of adults (22 years of age or older) with small and medium wide-necked (neck width ≥ 4 mm or dome-to-neck ratio \< 2) saccular or fusiform intracranial aneurysm (IAs) arising from a parent vessel with a diameter ≥ 2.0 mm and ≤ 5.0 mm.
Study: NCT05145361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B001 injection
Description: B001 injection 50mg/5mL Intravenous solution

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 5mL Intravenous solution
Study: NCT05440448

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Patch-free occlusion therapy
Description: Use of filters in glasses to provide occlusion therapy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Adhesive patch
Description: Standard-of-care occlusion therapy with an adhesive patch
Study: NCT05507879

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: OTHER
Intervention: Electronic Medical Record
Description: Review of medical records
Study: NCT05353257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX10
Description: Serplulimab is an innovative monoclonal antibody targeting PD-1，developed by Shanghai Henlius Biotech, Inc.~300mg Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin/cisplatin-etoposide
Description: Etoposide: 100 mg/m2, IV, on Days 1, 2, and 3 of each cycle. Carboplatin: AUC = 5, IV, on Day 1 of each cycle up to a dose of 750 mg. investigator's choice.~Cisplatin: 75mg/m2, IV, on Days 1 of each cycle. investigator's choice.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: carboplatin/cisplatin-etoposide
Description: Etoposide: 100 mg/m2, IV, on Days 1, 2, and 3 of each cycle. Carboplatin: AUC = 5, IV, on Day 1 of each cycle up to a dose of 750 mg. investigator's choice.~Cisplatin: 75mg/m2, IV, on Days 1 of each cycle. investigator's choice.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Thoracic radiotherapy
Description: Standard Thoracic Radiotherapy

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Thoracic radiotherapy
Description: Standard Thoracic Radiotherapy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Q3W

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Prophylactic Cranial Irradiation (PCI)
Description: PCI will be strongly recommended for participants who achieve CR or PR after completion of chemoradiation treatment.

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Prophylactic Cranial Irradiation (PCI)
Description: PCI will be strongly recommended for participants who achieve CR or PR after completion of chemoradiation treatment.
Study: NCT04919226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-Edotreotide (Peptide Receptor Radionuclide Therapy) PRRT
Description: Peptide Receptor Radionuclide Therapy (PRRT) using 177Lu-edotreotide with a defined number of cycles will be administered.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CAPTEM (Capecitabine and Temozolomide)
Description: Best standard of care treatment (investigator's choice \[from the protocol comparator list\]) according to individual risk-benefit assessment, institutional protocols, the local Prescribing Information, local regulations, or the local guidelines.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Amino-Acid Solution
Description: The Amino-Acid Solution (AAS) to be used in this study will contain a mixture of lysine and arginine diluted in an electrolyte solution.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus
Description: Best standard of care treatment (investigator's choice \[from the protocol comparator list\]) according to individual risk-benefit assessment, institutional protocols, the local Prescribing Information, local regulations, or the local guidelines.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX (Folinic acid + Fluorouracil + Oxaliplatin)
Description: Best standard of care treatment (investigator's choice \[from the protocol comparator list\]) according to individual risk-benefit assessment, institutional protocols, the local Prescribing Information, local regulations, or the local guidelines.
Study: NCT05008484

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NMES
Description: Subjects will undergo 4.5 months of open kinematic chain resistance training followed by 4.5 months of closed kinematic chain using simple rowing approach

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: 2000IU oral vitamin D supplementation daily for 9 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: 2000IU oral vitamin D supplementation daily for 9 months

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Passive movement
Description: Subjects will perform simple passive movement exercise for their legs while sitting in their wheelchairs at their home. The frequency of the training will be twice weekly. .
Study: NCT04982497

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video game based intervention
Description: The intervention will be administered via an online graphic-adventure video game. It includes 3 components: depression prevention, cognitive stimulation, and healthy habits promotion. The depression prevention component will be adapted from an indicated prevention program based on the model by Lewinsohn et al. (1985). The cognitive stimulation component is based on cognitive reserve (Tucker \& Stern, 2011) and neuroplasticity (Shapiro, 2001), the cognitive stimulation model by Spector et al. (2006), and the causes of age-related memory failures (Light, 1991) (e.g., decrease in the processing resources, semantic coding deficit, difficulties in deliberate information retrieval). The healthy habits promotion component is based on the social learning and social cognitive theories (Bandura, 1986; Spiegler, 2016).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: The active control group will have access to a platform of online therapeutically inactive information related to active aging.
Study: NCT06138925

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Analysis of walking
Description: 3-dimensional gait analysis with inertial measurement units (IMUs) on flat ground at different speeds (slow, comfortable and fast)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Analysis of running
Description: analysis of running on flat ground at different speeds (comfortable and fast)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Analysis of walking
Description: 3-dimensional gait analysis with inertial measurement units (IMUs) on flat ground at spontaneous speed (comfortable).
Study: NCT06391853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: A venous line will be installed and an MRI-compatible EEG Cap (32 scalp electrodes) will be installed with conductive gel between the scalp and the electrode.~Participants will receive 2 Intranasal spray. Participants will then be installed in the PET/MRI camera. At 30 min post INI administration, a continuous infusion of FDG will be started, along with dynamic PET acquisition while recording EEG and fMRI sequences. Participant will be asked to rest, eyes opened and awake to stay awake during the 55 minutes.~At the end of the neuroimaging data acquisition, participants will be freed from EEG Cap and will undergo neuropsychologic evaluation.The final part of neuropsychological evaluation will be performed on week later, on the phone.. The total study time for each scanning day will be around 3h.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: A venous line will be installed and an MRI-compatible EEG Cap (32 scalp electrodes) will be installed with conductive gel between the scalp and the electrode.~Participants will receive 2 Intranasal spray. Participants will then be installed in the PET/MRI camera. At 30 min post INI administration, a continuous infusion of FDG will be started, along with dynamic PET acquisition while recording EEG and fMRI sequences. Participant will be asked to rest, eyes opened and awake to stay awake during the 55 minutes.~At the end of the neuroimaging data acquisition, participants will be freed from EEG Cap and will undergo neuropsychologic evaluation.The final part of neuropsychological evaluation will be performed on week later, on the phone.. The total study time for each scanning day will be around 3h.
Study: NCT05321082

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1015550
Description: BI 1015550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1015550
Description: BI 1015550

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05500170

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nicotinamide riboside
Description: Nicotinamide riboside (NR) is a form of vitamin B3, which is found in fruits, vegetables, meat, and milk. NR is converted into nicotinamide adenosine dinucleotide NAD+. Low NAD+ levels have been linked to Alzheimer's disease and sleep disturbances.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo pill will contain micro cellulose powder.
Study: NCT04243941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-HBED-CC-PSMA
Description: Radioactive tracer used during imaging to help detect PSMA expressing tumor cells
Study: NCT05011292

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Video about SCB
Description: 3-4 minutes video about SCB.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Survey on child feeding and related knowledge and practices
Description: Short survey about infant feeding practices (3-4 minutes). No identifying information will be collected. The general scope of topics covered in the surveys will be attitudes toward the sugar-containing beverage reduction (SCB) videos played at the clinic as well as SCB knowledge and practices of parents and their children.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Survey on child feeding and related knowledge and practices
Description: Short survey about infant feeding practices (3-4 minutes). No identifying information will be collected. The general scope of topics covered in the surveys will be attitudes toward the sugar-containing beverage reduction (SCB) videos played at the clinic as well as SCB knowledge and practices of parents and their children.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational Video other than SCB
Description: Educational video about a topic other than infant SCB consumption.
Study: NCT06467799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant HAIC and PD-1 Plus Adjuvant PD-1
Description: Patients will first receive two cycles of FOLFOX-HAIC combined with tislelizumab as neoadjuvant therapy, with a 3-week interval between cycles. Two weeks after completing the neoadjuvant therapy, imaging assessments will be conducted to evaluate treatment efficacy and surgical feasibility. Surgical resection should be performed within two weeks following the imaging assessment. Four weeks post-resection, patients will undergo a follow-up evaluation to assess postoperative recovery and determine the presence of any residual tumor. If no residual or recurrent tumor is detected, adjuvant therapy with tislelizumab will commence (every three weeks, for a total of four cycles).
Study: NCT05782881

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: phone calls and encouraging patients' lifestyle change and medication adherence
Description: Use some methods to strictly intervene blood glucose , blood pressure and blood lipids for protocol treatment group people.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Statin
Description: Treatment and management according to the guidelines

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Statin
Description: Treatment and management according to the guidelines
Study: NCT05948176

Intervention type: OTHER
Intervention: The Bruininks-Oseretsky Test of Motor Proficiency, Second Edition
Description: It is a standardized measure of fine and gross motor skills in children and youth aged 4-21 years

Intervention type: OTHER
Intervention: The Bruininks-Oseretsky Test of Motor Proficiency, Second Edition
Description: It is a standardized measure of fine and gross motor skills in children and youth aged 4-21 years

Intervention type: OTHER
Intervention: The Bruininks-Oseretsky Test of Motor Proficiency, Second Edition
Description: It is a standardized measure of fine and gross motor skills in children and youth aged 4-21 years

Intervention type: OTHER
Intervention: The Bruininks-Oseretsky Test of Motor Proficiency, Second Edition
Description: It is a standardized measure of fine and gross motor skills in children and youth aged 4-21 years
Study: NCT05998629

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: a skin-interfaced colorimetric bifluidic sweat device with two synchronous channels
Description: a skin-interfaced colorimetric bifluidic sweat device with two synchronous channels
Study: NCT05118906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BP1.4979 active drug
Description: 2 tablets 15 mg of BP1.4979 per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 tablets of placebo per day
Study: NCT05370222

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary weight loss intervention
Description: Based on an energy assessment from the data collected at T0 (energy intake, physical activity level, and resting metabolism), individualized nutritional advice will be given during an interview in order to propose a dietary rebalancing and a light caloric restriction. Caloric restriction will be generated to decrease body weight by ≈ 0.5 to 1 kg per week, as advised in several publications. As for the dietary rebalancing, it will concern in particular the distribution of macronutrients and their nature (glycemic index, nature of lipids), the fibers intake, or the reduction of consumption of refined and/or energy-dense foods based on the ANSES Recommended Dietary Allowances and on the food consumption guidelines of the National Nutrition and Health Program.
Study: NCT05998629

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: a skin-interfaced colorimetric bifluidic sweat device with two synchronous channels
Description: a skin-interfaced colorimetric bifluidic sweat device with two synchronous channels

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care laboratory procedure for measurement of sweat
Description: a skin-interface sweat measurement using a smart-watch type device

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care laboratory procedure for measurement of sweat
Description: a skin-interface sweat measurement using a smart-watch type device
Study: NCT05005897

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cyanocobalamin
Description: Intramuscular injection of 400 µg cobalamin to children with elevated thcy at enrollment
Study: NCT05390593

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iTBS-1800
Description: Participants in the 1800-pulse intermittent TBS (iTBS-1800) active stimulation group will receive three-pulse 50-Hz pulses for 2 weeks at an intensity of 80% active motor threshold (MT) to Left DLPFC, twice a day. Stimulation will use a MAG \& More stimulator.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iTBS-1200
Description: Participants in the 1200-pulse intermittent TBS (iTBS-1200) active stimulation group will receive three-pulse 50-Hz pulses for 2 weeks at an intensity of 80% active motor threshold (MT) to Left DLPFC, twice a day. Stimulation will use a MAG \& More stimulator.
Study: NCT04897360

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Increased breathing
Description: hyperventilation to lower ETCO2
Study: NCT06530732

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deep Cervical lymphatlc-Venous Anastomosis Surgery
Description: Cervical deep lymphatic-venous anastomosis (dcLVA) can promote the flow of cerebrospinal fluid within the glymphatic system. The procedure involves connecting deep cervical lymphatic vessels to veins, reducing pressure on lymph nodes and allowing lymphatic fluid from high-pressure vessels to flow into the lower-pressure venous system. This surgical intervention enhances the clearance of waste in the glymphatic system, particularly amyloid-beta (Aβ) and tau proteins. By facilitating the removal of these AD-associated proteins from the brain, dcLVA can reduce local tissue fibrosis and cervical nerve compression, potentially reversing degenerative changes, slowing disease progression, and improving the quality of life for AD patients.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lecanemab
Description: The newly approved anti-beta-amyloid (Aβ) monoclonal antibody Lecanemab can delay AD progression but is only suitable for patients in the early stages. For those with moderate to severe AD, Lecanemab is not effective.
Study: NCT06415812

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Evolutionary Systems Therapy
Description: Evolutionary Systems Therapy is an individual form of psychotherapy (talk therapy) that has been previously tested trough a randomized controlled trial and a few cases series, confirming its feasibility and safety.
Study: NCT05312632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Safinamide Mesilate
Description: Safinamide Mesilate oral tablets.
Study: NCT04303078

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Varying levels of harness support during walking
Description: Participants will complete a standard gait and motion analysis at varying levels of harness support and stabilization (low, moderate, and high levels).

Intervention type: OTHER
Group type: OTHER
Intervention: Varying levels of harness support during walking
Description: Participants will complete a standard gait and motion analysis at varying levels of harness support and stabilization (low, moderate, and high levels).
Study: NCT05617066

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive behavioral therapy
Description: With the cognitive behavioral therapy will work on different aspects for coping and tools psychological stress.
Study: NCT04149977

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Therapy with pressure cuff
Description: 6 weeks of physical therapy will have similar exercises to standard therapy however the patients will use a cuff around the affected leg during the exercises.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Physical Therapy with placebo pressure cuff
Description: 6 weeks of physical therapy will have similar exercises to standard therapy however the patients will use a pressure cuff around the affected leg during the exercises. The pressure cuff will have 50% of the pressure that will be considered effective.
Study: NCT04897360

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sharpened Romberg test (SRT)
Description: Balance test conducted by standing with feet in front of each other, heel-to-toe in line while the right hand is on the left shoulder and the left hand is on the right shoulder.
Study: NCT06436482

Intervention type: DEVICE
Intervention: Optical Coherence Tomography
Description: Placing the probe of OCT in RB10c through the working channel of bronchoscope for real time dynamic scanning and collecting OCT parameters from participants in different groups.

Intervention type: DEVICE
Intervention: Optical Coherence Tomography
Description: Placing the probe of OCT in RB10c through the working channel of bronchoscope for real time dynamic scanning and collecting OCT parameters from participants in different groups.
Study: NCT06025513

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Embrace Patch
Description: Tension offloading skin patch
Study: NCT05174221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mezagitamab
Description: TAK-079 subcutaneous injection.